CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 241 enrolled
Drug / intervention
VeSTALdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03640286
NCT03640286N/ACompleted

Clinical Investigation Protocol for the Demonstration of Safety and Efficacy of VeSTAL Weight Loss Device in Human Subjects. Randomized Study of VeSTAL in Patients Who Are Overweight

Neurovalens Ltd.·interventional·Posted Aug 21, 2018·Updated Mar 12, 2025

In Brief

A clinical study evaluating VeSTAL for Obesity. Completed, enrolled 241 participants across 4 sites in 2 countries.

Detailed Summary

A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), combined with a lifestyle modification program, compared to a sham control and a lifestyle modification program as a means of reducing excess body weight and body fat. The purpose of this investigation device study is to collect data to support regulatory submissions, primarily in the United States of America (USA), but it may also be used to support submissions in other regions, including the European Union (EU).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited Kingdom, United States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 21, 2018
Enrollment StartAug 23, 2019
Primary CompletionApr 26, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.9 years ago

Interventions

VeSTALdevice

The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.